期刊
MEDICAL MYCOLOGY
卷 59, 期 10, 页码 1048-1051出版社
OXFORD UNIV PRESS
DOI: 10.1093/mmy/myab037
关键词
antifungal agents; epidemiology; infant; candidiasis; antimicrobial stewardship
资金
- Australian Commission on Safety and Quality in Heath Care
- University of Melbourne
- NHMRC Career Development Fellowship [APP1111596]
- Australian Government Research Training Program Scholarship
The study revealed that Australian neonates commonly receive antifungal medications, primarily oral nystatin for prophylactic rather than treatment purposes, with invasive fungal infections being rare. There is substantial variation in dosing of antifungal drugs nationally.
We describe contemporary antifungal use in neonates, with point-prevalence survey data from the National Antimicrobial Prescribing Survey across Australian hospitals from 2014 to 2018. There were 247 antifungal prescriptions in 243 neonates in 20 hospitals, median age six days (range 0-27 days). In 219/247 prescriptions (89%) antifungals were prescribed as prophylaxis. Topical (oral) nystatin was the most frequently prescribed in 233/247 prescriptions (94%), followed by fluconazole 11/247 (4%), with substantial variation in dosing for both. Two of 243 neonates (0.8%) had invasive fungal infection. Nystatin use dominates current antifungal prescribing for Australian neonates, in contrast to other countries, and invasive fungal infection is rare. Lay summary Novel nationwide surveillance found newborn infants in Australian hospitals commonly receive antifungal medications, mostly oral nystatin. This is given mainly to prevent rather than treat infection, which is rare. There is substantial unexplained variation in dosing of antifungal drugs nationally.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据